State Board of Administration of Florida Retirement System maintained its position in Theravance Biopharma, Inc. (NASDAQ:TBPH) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,478 shares of the biopharmaceutical company’s stock at the close of the second quarter. State Board of Administration of Florida Retirement System’s holdings in Theravance Biopharma were worth $1,015,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of TBPH. Wells Fargo & Company MN increased its stake in shares of Theravance Biopharma by 10.6% in the first quarter. Wells Fargo & Company MN now owns 32,270 shares of the biopharmaceutical company’s stock valued at $1,188,000 after buying an additional 3,100 shares during the period. American Century Companies Inc. acquired a new position in shares of Theravance Biopharma in the first quarter valued at approximately $1,132,000. Bank of New York Mellon Corp increased its stake in shares of Theravance Biopharma by 2.6% in the first quarter. Bank of New York Mellon Corp now owns 206,023 shares of the biopharmaceutical company’s stock valued at $7,586,000 after buying an additional 5,188 shares during the period. Swiss National Bank increased its stake in shares of Theravance Biopharma by 1.7% in the first quarter. Swiss National Bank now owns 64,442 shares of the biopharmaceutical company’s stock valued at $2,373,000 after buying an additional 1,100 shares during the period. Finally, Parametric Portfolio Associates LLC increased its stake in shares of Theravance Biopharma by 3.3% in the first quarter. Parametric Portfolio Associates LLC now owns 14,090 shares of the biopharmaceutical company’s stock valued at $519,000 after buying an additional 456 shares during the period. 84.84% of the stock is owned by hedge funds and other institutional investors.

In other Theravance Biopharma news, EVP Bradford J. Shafer sold 14,670 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total value of $451,395.90. Following the completion of the sale, the executive vice president now owns 134,327 shares in the company, valued at $4,133,241.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Frank Pasqualone acquired 4,000 shares of the stock in a transaction on Monday, August 21st. The stock was bought at an average price of $26.34 per share, with a total value of $105,360.00. Following the transaction, the senior vice president now directly owns 213,180 shares of the company’s stock, valued at approximately $5,615,161.20. The disclosure for this purchase can be found here. Insiders purchased a total of 20,000 shares of company stock valued at $494,300 in the last 90 days. 6.10% of the stock is currently owned by corporate insiders.

Several research analysts have recently issued reports on TBPH shares. Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a research note on Wednesday, July 19th. ValuEngine raised Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub raised Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Zacks Investment Research raised Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, September 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Theravance Biopharma in a research note on Wednesday, August 2nd. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $41.86.

Shares of Theravance Biopharma, Inc. (TBPH) opened at 33.49 on Friday. Theravance Biopharma, Inc. has a 52-week low of $23.15 and a 52-week high of $43.44. The firm’s market cap is $1.80 billion. The firm’s 50-day moving average is $29.57 and its 200-day moving average is $35.29.

ILLEGAL ACTIVITY NOTICE: This article was published by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.watchlistnews.com/theravance-biopharma-inc-tbph-position-maintained-by-state-board-of-administration-of-florida-retirement-system/1581755.html.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.